Pi­lot project pro­vides a snap­shot of ef­fec­tive­ness of Pfiz­er’s PARP con­tender ta­la­zoparib

You can ex­pect some no­table re­search up­dates on the slate of late-stage PARP in­hibitors at this week­end’s an­nu­al Eu­ro­pean So­ci­ety of Med­ical On­col­o­gy meet­ing. And an ear­ly teas­er on what’s to come at ES­MO should help whet every­one’s ap­petite for more.

Jen­nifer Lit­ton, the prin­ci­pal in­ves­ti­ga­tor in the Phase III ta­la­zoparib study and an in­ves­ti­ga­tor at MD An­der­son Can­cer Cen­ter, set up a small pi­lot study that used the PARP in­hibitor on a group of 13 breast can­cer pa­tients with BR­CA mu­ta­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER